Jim Cramer - Mad Money Summit Therapeutics SMMT-Q DON'T BUY Sep 12, 2025

The results of their cancer screening drug were poor

Move on.

Jim Cramer - Mad Money

Unlock Rating

$18.940

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Doesn't make money and is a risky spec.

Most Recent Experts

Andrey Omelchak

LionGuard Capital Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase Insights

5i Research

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Jim Cramer - Mad Money Summit Therapeutics SMMT-Q DON'T BUY Sep 12, 2025

You might be interested:

Summit Therapeutics(SMMT-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Andrey Omelchak

The Panic-Proof Portfolio (Stockchase Research)

Larry Berman CFA, CMT, CTA

Stockchase Insights

Jim Cramer - Mad Money